Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.60 |
| ▸ | HTR3A | P46098 | 5/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.51 |
| ▸ | HTR3B | O95264 | 4/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200146 | 1.00 | ALDH1A1 (0.61) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7063896 | 0.90 | ALDH1A1 (0.54) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7059425 | 0.90 | ALDH1A1 (0.59) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL4193845 | 0.88 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL4193847 | 0.88 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7129346 | 0.88 | ALDH1A1 (0.70) | ALDH1A1POLBCHRNA7HTR3A | |
| SCHEMBL7059848 | 0.88 | ALDH1A1 (0.57) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7063959 | 0.88 | ALDH1A1 (0.61) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7058291 | 0.88 | ALDH1A1 (0.61) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7063801 | 0.87 | ALDH1A1 (0.63) | ALDH1A1POLBCHRNA7HTR3AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545537-B9 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | claimed |
| EP-1545537-B1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | EP | claimed |
| US-7001914-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | claimed |
| US-20050256146-A1 | Alpha-7 nicotinic receptor agonists and stains in combination | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1545537-A1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | claimed |
| US-20040259909-A1 | Treatment of fibromyalgia syndrome | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | claimed |
| WO-2004019947-A1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | claimed |
| EP-1259508-B1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2003-10-15 | — | — | EP | claimed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | claimed |
| EP-1259508-A1 | NOVEL BIARYLCARBOXAMIDES | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060821-A1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | claimed |
| US-20090192180-A1 | Alpha-7 Nicotinic Receptor Agonists and Statins In Combination | KEITH RICHARD | 2009-07-30 | — | — | US | disclosed |
| US-7491734-B2 | 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands | ASTRAZENECA AB (SE) | 2009-02-17 | — | — | US | disclosed |
| EP-1545537-B9 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149563-A1 | New Compounds | PHILLIPS EIFION | 2007-06-28 | — | — | US | disclosed |
| WO-2004019947-A1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
| EP-1259508-B1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | disclosed |
| EP-1259508-A1 | NOVEL BIARYLCARBOXAMIDES | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060821-A1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149563-A1 | New Compounds | DRD1, DRD2, GRIN2A | ALDH1A1 137/4885POLB 3912/4885CHRNA7 145/4885 |
| US-20030008867-A1 | Compounds | DRD2, DRD1, GRIN2A | ALDH1A1 75/4885POLB 3437/4885CHRNA7 209/4885 |
| US-20040259909-A1 | Treatment of fibromyalgia syndrome | CHRNA7, CHRNA5, CHRNA10 | ALDH1A1 3093/4885POLB 4199/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.